FTLFNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
FITLIFE BRANDS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.23−0.16 (-1.91%)
Close on Oct 19, 2026
- Market cap
- $81.53M
- P/E (TTM)
- 43.3
- Dividend yield
- –
FITLIFE BRANDS, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Legacy FitLife [Member] | $15.94M | $64.47M | $28.08M | 100.0% | -75.3% |
| Irwin [Member] | $0 | $0 | – | 0.0% | – |
| MRC [Member] | – | $29.04M | $24.37M | – | – |
| Muscle Pharm [Member] | – | $10.05M | $253.00K | – | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| United States | $77.40M | $61.47M | $48.99M | 485.7% | +25.9% |
| Non-US [Member] | $4.06M | $3.00M | $3.71M | 25.5% | +35.5% |
From the segment and revenue-disaggregation notes of Fitlife Brands's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.